MARKET

PROK

PROK

ProKidney
NASDAQ
1.600
-0.170
-9.60%
After Hours: 1.700 +0.1 +6.25% 19:48 03/27 EDT
OPEN
1.760
PREV CLOSE
1.770
HIGH
1.760
LOW
1.580
VOLUME
1.51M
TURNOVER
--
52 WEEK HIGH
7.13
52 WEEK LOW
0.4603
MARKET CAP
483.07M
P/E (TTM)
-3.1068
1D
5D
1M
3M
1Y
5Y
1D
ProKidney appoints Greg Madison as chief commercial officer
TipRanks · 3d ago
ProKidney appoints Greg Madison chief commercial officer; senior leadership team expands
Reuters · 3d ago
Press Release: ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
Dow Jones · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), LENZ Therapeutics (LENZ) and Sarepta Therapeutics (SRPT)
TipRanks · 3d ago
Weekly Report: what happened at PROK last week (0316-0320)?
Weekly Report · 5d ago
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
TipRanks · 03/20 06:01
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY)
TipRanks · 03/19 13:20
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)
TipRanks · 03/19 11:17
More
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Webull offers ProKidney Corp stock information, including NASDAQ: PROK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROK stock methods without spending real money on the virtual paper trading platform.